SAE

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Annual, Conference, Significance, Patient, Standard of care, Șaeș, PDAC, Toxicity, AACR, Survivor, Pancreatic cancer, Therapy, Infrared spectroscopy correlation table, SAE, Medicine, Pharmaceutical industry

CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or the “Company,” Nasdaq: QLGN) today announces that a poster featuring its early clinical experience with a novel first-in-class G-Quadruplex experimental anti-cancer drug, QN-302, was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California.

Key Points: 
  • CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or the “Company,” Nasdaq: QLGN) today announces that a poster featuring its early clinical experience with a novel first-in-class G-Quadruplex experimental anti-cancer drug, QN-302, was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California.
  • Dose escalation initiated (patient #101-004) after three patients successfully completed cycle 1 of the initial dose.
  • Dose escalation will be continued, with more patients being enrolled in the coming months.
  • One patient was withdrawn from study 3/1/2024 after 4 months of stable disease.

Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Men, Health, Consumer, Other Health, Pharmaceutical, Surgery, Other Science, Research, Medical Devices, Science, Women, Seniors, Clinical Trials, Week, Sciatica, LDH, Incidence, Ferring Pharmaceuticals, Patient, Spinal disc herniation, Șaeș, University, ESI, Quality of life, Manager, University of Illinois Urbana-Champaign, Society, Back pain, LSM, Pain, SAE

"Based on these findings, SI-6603 could provide another option where a single injection to the lumbar disc could offer patients significant relief from the unrelenting pain often associated with lumbar disc herniation."

Key Points: 
  • "Based on these findings, SI-6603 could provide another option where a single injection to the lumbar disc could offer patients significant relief from the unrelenting pain often associated with lumbar disc herniation."
  • An analysis assessing current treatment patterns and gaps in clinical management of patients with newly diagnosed LDH was also presented.
  • The analysis reviewed medical claims data of more than a million U.S. patients over a four-year period.
  • Among patients who received more than one ESI, one in five (22.4%) underwent surgery with 14.2% of those patients receiving repeated surgeries.

RAPID + TCT Sets Strategic Direction, Releases Schedule for 2024-26 Events

Retrieved on: 
Wednesday, March 20, 2024
Government, TCT, Wood, Growth, Original equipment manufacturer, Partnership, WCX, Research, Artificial intelligence, ASTM, Hollywood Showcase, RAPID, City, Robotics, RSNA, ARMI, SME, 3D printing, Machine learning, SAE, Convention center, Engineering, Printing, Video game

In 2026, RAPID + TCT will take place April 14-16 in Boston for the first time at the Boston Convention & Exhibition Center.

Key Points: 
  • In 2026, RAPID + TCT will take place April 14-16 in Boston for the first time at the Boston Convention & Exhibition Center.
  • “It’s important that we signpost to the industry what our plans are,” said Duncan Wood, Rapid News Group CEO.
  • For more details about this year’s edition of RAPID + TCT, visit rapid3devent.com .
  • Additional details about the 2025 and 2026 editions of RAPID + TCT, including information for exhibitors, will be available soon.

Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML

Retrieved on: 
Monday, March 18, 2024
Principal, Nasdaq First North, Survival, ASH, AML, Associate, Webcast, Patient, Acute myeloid leukemia, Doctor of Philosophy, MD, Quality of life, Myelodysplastic syndrome, Faron Pharmaceuticals, HMA, Myelocyte, Society, Helsinki University Central Hospital, Azacitidine, MDS, MCR, FDA, AIM, SAE, Pharmaceutical industry

TURKU, Finland and BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today provided further data from patients treated during the Phase 1 part of the ongoing BEXMAB trial that has moved into Phase 2 for higher-risk (HR) myelodysplastic syndrome (MDS) patients failed on previous hypomethylating agent (HMA).

Key Points: 
  • Latest readout of the BEXMAB study shows more responding patients and good durability of remission amongst HR HMA-failed MDS patients.
  • 4/5 of the initial Phase 1 HR HMA-failed MDS patients were still alive after eight months of follow-up.
  • Faron will be hosting a virtual webinar to discuss the additional data tomorrow, Tuesday, 19 March at 11.00 EET/9am GMT.
  • After the already reported 5 HMA-failed HR MDS patients, 3 new HMA-failed HR MDS patients were enrolled, filling the remaining Phase 1 slots.

Volkswagen ADMT Announces Agreement With Mobileye for Autonomous Driving

Retrieved on: 
Wednesday, March 20, 2024
Hardware, Autonomous Driving, Vehicles, Automotive, Artificial Intelligence, Technology, Automotive Manufacturing, General Automotive, Manufacturing, Commercial vehicle, Freedom, Mobileye, SDS, Bulli, Volkswagen Group, Volkswagen, Volkswagen Commercial Vehicles, Keirsey Temperament Sorter, Economic development, Transport, Software, Quality of life, Society, Caddy, City, Radar, Mobility, ID, ARG, Multimedia, MOIA, Level 4, SAE, Transporter, Police

Following an extensive pilot phase with road testing in Germany and the USA, Volkswagen ADMT GmbH, part of Volkswagen AG, is announcing a cooperation agreement with the technology company Mobileye Global Inc. Mobileye shall develop and supply software, hardware components and digital maps for the self-driving ID.

Key Points: 
  • Following an extensive pilot phase with road testing in Germany and the USA, Volkswagen ADMT GmbH, part of Volkswagen AG, is announcing a cooperation agreement with the technology company Mobileye Global Inc. Mobileye shall develop and supply software, hardware components and digital maps for the self-driving ID.
  • The aim of Volkswagen ADMT GmbH is to develop the fully electric autonomous ID.
  • Volkswagen ADMT GmbH is working intensively on autonomous freight transport for various industries as a second important pillar alongside autonomous passenger transport.
  • Within the Volkswagen Group, VWCV is also the lead brand for autonomous driving and mobility offerings such as Mobility-as-a-Service and Transport-as-a-Service - areas in which we are shaping the future of mobility.

Aurora to Showcase Driverless Trucks Navigating Advanced Road Scenarios at Analyst and Investor Day

Retrieved on: 
Thursday, March 14, 2024
Vehicle Technology, Fleet Management, Robotics, General Automotive, Technology, Autonomous Driving, Vehicles, Automotive, Trucking, Automotive Manufacturing, Transport, Other Technology, Manufacturing, Volvo, Safety case, VNL, Webcast, OEM, Aurora Innovation, Analyst, Safety, Multimedia, SAE, Cryptocurrency

Today, Aurora Innovation (NASDAQ: AUR) is holding an Analyst and Investor Day at its headquarters in Pittsburgh where executives will share the company’s progress toward driverless deployment and its path to gross profit, scale and self-funding.

Key Points: 
  • Today, Aurora Innovation (NASDAQ: AUR) is holding an Analyst and Investor Day at its headquarters in Pittsburgh where executives will share the company’s progress toward driverless deployment and its path to gross profit, scale and self-funding.
  • For the first time, the company will publicly show the Aurora Driver – an SAE Level 4 autonomous driving system – navigating safety-critical scenarios without anyone on board.
  • View the full release here: https://www.businesswire.com/news/home/20240314168414/en/
    Aurora to Showcase Driverless Trucks Navigating Advanced Road Scenarios at Analyst and Investor Day (Photo: Business Wire)
    “Building on years of development and testing, our work toward the safe and scalable deployment of driverless trucks is nearing a historic milestone,” said Chris Urmson, CEO and co-founder of Aurora.
  • Aurora’s Analyst and Investor Day presentation will be available on a live webcast on Aurora’s investor relations website at ir.aurora.tech , with a replay available for 30 days following the live presentation.

SA World Launches on Injective to Boost Value of Gaming Ecosystem

Retrieved on: 
Thursday, March 28, 2024
ASG, Web3, RPG, L1, Growth, Dew, Binance, NFT, Non-fungible token, Injective function, Decentralized finance, Polygon, Ecosystem, SDK, Blockchain, SAE, Cryptocurrency

NEW YORK, March 28, 2024 /PRNewswire/ -- Injective, the blockchain built for decentralized finance, today announced the launch of SA World, its latest effort to incorporate GameFi into its industry-leading DeFi infrastructure. Developed by OneChain Studios and backed by prominent ventures such as Pantera, Coinbase, and Spartan Capital, SA World, previously one of the largest gaming networks on Polygon and BNB Chain, is the one-stop Web3 gaming destination offering an extensive selection of rewarding games alongside a comprehensive suite of streamlined and efficient game management tools.

Key Points: 
  • The launch on Injective is a major move in supercharging the web3 gaming ecosystem.
  • Powering the gaming ecosystem's growth is Injective's groundbreaking L1 blockchain network, featuring lowest transaction costs and subsecond block times.
  • "SA World's launch on Injective marks a significant stride towards enhancing the economic infrastructure for GameFi," said Eric Chen, CEO and co-founder of Injective Labs.
  • Integration into Injective immediately opens SA World's and Injective's ecosystems to 150,000 account holders and 7,000 NFT holders of SA World.

LeddarTech Strengthens Collaboration With Arm, Showcasing ADAS Innovations at Embedded World 2024 on April 9-11 in Nuremberg, Germany

Retrieved on: 
Wednesday, March 27, 2024
Arm, Original equipment manufacturer, Partnership, Embedded, ADAS, ARM, Texas Instruments, Arm (company), NCAP, SAE

LeddarTech will join Arm at Embedded World on April 9-11, 2024, following the announcement on March 13, 2024 between the two industry leaders where LeddarTech shared it would be enabling its LeddarVision technology using the latest Arm Automotive Enhanced® (AE) technology.

Key Points: 
  • LeddarTech will join Arm at Embedded World on April 9-11, 2024, following the announcement on March 13, 2024 between the two industry leaders where LeddarTech shared it would be enabling its LeddarVision technology using the latest Arm Automotive Enhanced® (AE) technology.
  • During the Embedded World event, LeddarTech will showcase its cutting-edge technology, highlighting how the synergies between the two companies are dedicated to advancing the automotive industry.
  • The demonstration illustrates LeddarTech and Arm's collaborative efforts to empower OEMs and Tier 1s in efficiently utilizing Arm's latest AE compute technology and software solutions.
  • LeddarTech demonstrates its advanced AI-based sensor fusion and perception software, LeddarVision, in conjunction with the cutting-edge Arm AE technology .

LeddarTech Strengthens Collaboration With Arm, Showcasing ADAS Innovations at Embedded World 2024 on April 9-11 in Nuremberg, Germany

Retrieved on: 
Wednesday, March 27, 2024
Arm, Original equipment manufacturer, Partnership, Embedded, ADAS, ARM, Texas Instruments, Arm (company), NCAP, SAE

LeddarTech will join Arm at Embedded World on April 9-11, 2024, following the announcement on March 13, 2024 between the two industry leaders where LeddarTech shared it would be enabling its LeddarVision technology using the latest Arm Automotive Enhanced® (AE) technology.

Key Points: 
  • LeddarTech will join Arm at Embedded World on April 9-11, 2024, following the announcement on March 13, 2024 between the two industry leaders where LeddarTech shared it would be enabling its LeddarVision technology using the latest Arm Automotive Enhanced® (AE) technology.
  • During the Embedded World event, LeddarTech will showcase its cutting-edge technology, highlighting how the synergies between the two companies are dedicated to advancing the automotive industry.
  • The demonstration illustrates LeddarTech and Arm's collaborative efforts to empower OEMs and Tier 1s in efficiently utilizing Arm's latest AE compute technology and software solutions.
  • LeddarTech demonstrates its advanced AI-based sensor fusion and perception software, LeddarVision, in conjunction with the cutting-edge Arm AE technology .

IAQG Publishes First IA Standard Through Global Publishing Partner SAE International

Retrieved on: 
Wednesday, February 21, 2024
Aviation, SAE International, IAQG, AQAP, EN, SAE, SJAC, Publication, Development, Workflow

Brussels, Belgium--(Newsfile Corp. - February 21, 2024) - The International Aerospace Quality Group® (IAQG) announced today the publication of the first International Aerospace (IA) standard, IA9137™: Guidance for the Application of AQAP 2110 within a 9100 Quality Management System.

Key Points: 
  • Brussels, Belgium--(Newsfile Corp. - February 21, 2024) - The International Aerospace Quality Group® (IAQG) announced today the publication of the first International Aerospace (IA) standard, IA9137™: Guidance for the Application of AQAP 2110 within a 9100 Quality Management System.
  • SAE International®, the organization's partner in developing international standards, has released IA9137 globally.
  • As part of this agreement, SAE is publishing IA9137 simultaneously in English, Spanish, German, French, Italian, Japanese, Chinese and Korean.
  • "The publication of IA9137 is a testament to the long-standing relationship between IAQG and SAE – and the worldwide consensus we foster.